title: Nitric oxide signaling in human ovarian cancer: A potential therapeutic target.
abstract: Ovarian cancer is the leading cause of death due to gynecologic malignancies worldwide. Current therapy regimens are ineffective to treat advanced ovarian cancers, presenting a need to develop novel therapeutic strategies. Nitric oxide (NO) is a multifunctional gaseous molecule that is generated by cancer, stromal and endothelial cells and plays a multifaceted role in cancer biology through multiple mechanisms. Accumulating evidence suggests that NO signaling is involved in multiple aspects of ovarian cancer, including growth, apoptosis, cancer-stromal cell interaction, angiogenesis and response to chemotherapy. This review will discuss the experimental and clinical evidence of the involvement of NO signaling in ovarian cancer and the therapeutic potential of targeting NO signaling in ovarian cancer.
authors.affiliation: Department of Oncology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada; Department of Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
authors.forename: Ahmed
authors.initials: A
authors.lastname: El-Sehemy
authors.affiliation: Department of Oncology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.
authors.forename: Lynne-Marie
authors.initials: LM
authors.lastname: Postovit
authors.affiliation: Department of Oncology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada; Department of Obstetrics and Gynecology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada. Electronic address: yangxin@ualberta.ca.
authors.forename: YangXin
authors.initials: Y
authors.lastname: Fu
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology; D017209:Apoptosis; D001391:Azo Compounds / Q000494:pharmacology; D014408:Biomarkers, Tumor / Q000378:metabolism; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D009569:Nitric Oxide / Q000378:metabolism*; D020030:Nitric Oxide Donors / Q000494:pharmacology; D052247:Nitric Oxide Synthase Type II / Q000378:metabolism; D010051:Ovarian Neoplasms / Q000378:metabolism* / Q000473:pathology; D015398:Signal Transduction; D000071756:Soluble Guanylyl Cyclase / Q000378:metabolism; D062366:para-Aminobenzoates / Q000494:pharmacology
chemical_list: D000970:Antineoplastic Agents; D001391:Azo Compounds; D014408:Biomarkers, Tumor; D020030:Nitric Oxide Donors; C485370:O(2)-(2,4-dinitro-5-(N-methyl-N-4-carboxyphenylamino)phenyl 1-N,N-dimethylamino)diazen-1-ium-1,2-diolate; D062366:para-Aminobenzoates; D009569:Nitric Oxide; D052247:Nitric Oxide Synthase Type II; D000071756:Soluble Guanylyl Cyclase
keywords: Diagnostic marker; Nitric oxide; Ovarian cancer; Therapeutic target; iNOS